Vaxart (STU:NB11) Tariff Resilience Score: 7/10 (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NB11 Vaxart Inc STU:NB11
49 GF Score
Price €0.60
! 3 Warning Signs
View Full Analysis

What is Vaxart Tariff Resilience Score?

Vaxart STU:NB11 49 Tariff Resilience Score is 7 as of Jul. 23, 2026. GuruFocus rates STU:NB11 with a GF Score™ of 49/100. The stock has 3 warning signs investors should review. Among 1,370 Biotechnology companies, Vaxart ranks better than 90.36% on this metric.

Vaxart has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Vaxart has Vaxart's primary focus on biotechnology and pharmaceuticals, with limited reliance on physical goods, reduces tariff exposure. Manufacturing is largely domestic, and the company can leverage alternative suppliers for raw materials. Historical tariff impacts have been minimal.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Vaxart might have Highly Resilient.

Vaxart  (STU:NB11) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Vaxart Tariff Resilience Score Related Terms

STU:NB11 vs SPRO, ADCT, GNLX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Vaxart's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxart Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Vaxart's Tariff Resilience Score falls into.


STU:NB11
49GF Score
Vaxart Inc STU:NB11
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Vaxart (STU:NB11) has a Tariff Resilience Score of 7 as of Jul. 23, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Vaxart ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Vaxart's Tariff Resilience Score too high?
Vaxart's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Vaxart's value of 7 is 75% above this industry median. Based on the distribution chart, Vaxart ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vaxart has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Vaxart's Tariff Resilience Score compare to SPRO and ADCT?
According to the Biotechnology industry distribution chart, Vaxart ranks #132 out of 1370 companies for Tariff Resilience Score. This places Vaxart in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Vaxart's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaxart's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaxart's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxart stock overvalued right now?
Vaxart (STU:NB11) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Vaxart's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Vaxart (STU:NB11), the current Tariff Resilience Score is 7 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
49GF Score

Get the complete analysis for STU:NB11

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price